Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $1,154 | 7-10 days | |
5 mg | $3,180 | 7-10 days |
Description | Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer. |
In vitro | 8 nM Mirvetuximab soravtansine in combination with Carboplatin treated IGROV-1 cells showed enhanced synergistic inhibition of growth and disruption of the cell cycle in vitro. [1] |
In vivo | Intravenous injection of 5 mg/kg Mirvetuximab soravtansine enhances the antitumor effect of Carboplatin in vivo using a xenograft model derived from SCID female mouse patients. [1] |
Alias | TAK-853, IMGN-853, IMGN853 |
Cas No. | 1453084-37-1 |
Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.